- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00054691
ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin
A Phase II Study of ZD1839 (Iressa), Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor, in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Skin
Studieoversigt
Detaljeret beskrivelse
ZD1839 is a new drug that may slow or stop cell growth in humans.
Epidermal growth factor receptor (EGFR) may be involved in certain types of cancer, including squamous cell carcinoma of the skin. When EGFR is stimulated, a series of chemical reactions starts that results in a tumor being "told" to grow. ZD1839 tries to stop these reactions by blocking EGFR. This may stop tumors from growing.
In this study, participants will take ZD1839 by mouth daily. Once the treatment has started, participants will return to the clinic before every treatment cycle (every 4 weeks) for the first 4 months then every 8 weeks thereafter. At these visits, participants will have a physical exam and blood tests will be performed. About 2-4 teaspoons of blood will be drawn at each visit. The doctor will also check on how participants are tolerating ZD1839 (side effects). Every 8 weeks, participants will have their tumor evaluated by radiographic scans. This may include either a CT or MRI and a chest X-ray.
During treatment, participants should not take any other medication, including non-prescription drugs such as aspirin or herbal products without the approval of their doctor.
Participants will continue taking the trial drug until the tumor grows, a severe side effect occurs, they withdraw consent, or the study is closed. The study will be closed 12 months after the last participant is enrolled.
This is an investigational study. The FDA has approved ZD1839 for the treatment of advanced lung cancer, but the FDA has authorized ZD1839 for research only in the treatment of skin cancer. About 40 participants will take part in this study. All will be enrolled at M.D. Anderson.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
Texas
-
Houston, Texas, Forenede Stater, 77030
- UT MD Anderson Cancer Center
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Provision of written informed consent.
- Pathologically confirmed locoregional recurrence and/or metastatic SCC of the skin not amenable to curative therapy (i.e., surgery or radiation).
- Evaluable and/or measurable disease. (Based on Union for International Cancer Control (UICC)/World Health Organization (WHO) Criteria)
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
- Adequate hematologic function as defined by an absolute neutrophil count >= 1,500/mm3, a platelet count >= 100,000/mm3, a white blood count (WBC) >= 3,000/ mm3, and a hemoglobin level of >= 9 g/dl.
- Up to one prior chemotherapy regimen.
- At least a 2-week recovery from prior therapy toxicity.
- Age 18 years or older.
- Disease free from a previously treated malignancy, other than the disease under study, for greater than 3 years. Patients with a history of a previous basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix, completely resected breast cancer will not be excluded.
- Women of childbearing potential and men must be willing to practice acceptable methods of birth control to prevent pregnancy.
Exclusion Criteria:
- Prior ZD1839 or other Epidermal growth factor receptor (EGFR) inhibiting agents.
- Other co-existing malignancies or malignancies diagnosed within the last 3 years with the exception of basal cell carcinoma or cervical cancer in situ.
- Any unresolved chronic toxicity greater then Common Terminology Criteria (CTC) grade 2 from previous anticancer therapy.
- Incomplete healing from previous oncologic or other major surgery.
- Concomitant use of phenytoin, carbamazepine, barbiturates, rifampicin, St John's Wort. Patients taking anticoagulants must have coagulation parameters followed (i.e., Prothrombin time (PT) or Partial thromboplastin time (PTT)).
- Absolute neutrophil count (ANC) less than 1,500/mm**3 or platelets less than 100,000/mm**3.
- Serum bilirubin greater than 1.25 times the upper limit of reference range (ULRR).
- In the opinion of the investigator, any evidence of severe or uncontrolled systemic disease, (e.g., unstable or uncompensated respiratory, cardiac, hepatic, or renal disease).
- Alanine amino transferase (ALT) or aspartate amino transferase (AST) greater than 2.5 times the ULRR if no demonstrable liver metastases or greater than 5 times the Upper Limit of the Reference Range (ULRR) in the presence of liver metastases.
- Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the trial.
- Pregnancy or breast feeding (women of child-bearing potential)
- The patient has an uncontrolled seizure disorder or active neurological disease.
- The patient has received any non-approved or investigational agent(s) within 30 days before Day 1 of study treatment.
- Known, severe hypersensitivity to ZD1839 or any of the excipients of this product.
- Any evidence of clinically active Interstitial Lung Disease (ILD) (patients with chronic, stable radiographic changes who are asymptomatic need not be excluded).
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Iressa (ZD1839)
Iressa (ZD1839) 250 mg by mouth daily.
|
250 mg by mouth daily
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Number of Participants With Objective Response (Partial Response, Stable Disease and Progressive Disease)
Tidsramme: Every 8 weeks till disease progression.
|
Responses were assessed according to the Union Internationale Contre le Cancer (UICC) / World Health Organization (WHO) criteria.
Objective response (measurable response) defined as: Partial response (PR): Applies only to participants with at least 1 measurable lesion; >/=50% decrease under baseline in sum of products of perpendicular diameters of all measurable lesions.
Stable Disease (SD): No progression of evaluable disease and/or no new lesions.
Progressive Disease (PD): 50% increase or an increase of 10 cm2 (whichever is smaller) in the sum of products of all measurable lesions overall smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease.
|
Every 8 weeks till disease progression.
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Duration of Response
Tidsramme: Every 8 weeks till disease progression.
|
Response duration was defined as the time from initial response during therapy to progression of disease.
|
Every 8 weeks till disease progression.
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Publikationer og nyttige links
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- ID02-282
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Hudkræft
-
Alma LasersTrukket tilbageSkin ResurfacingForenede Stater
-
R2 DermatologyAfsluttet
-
Syneron MedicalAfsluttetSkin Resurfacing | RynkereduktionForenede Stater, Canada
-
University of Split, School of MedicineAfsluttetSkin Recovery i forskellige humane hudskademodellerKroatien
-
Centre Hospitalier le MansRekruttering
-
The First Affiliated Hospital of Dalian Medical...UkendtSår og skader | Trauma | Brud, åben | Skin ExpanderKina
-
Integrative Skin Science and ResearchBurt's Bees Inc.RekrutteringAcne | Skin MicroboimeForenede Stater
-
PT. Daewoong InfionEquilab InternationalAfsluttetHudtransplantatar | Split-Thickness Skin Graft (STSG)Indonesien
-
Chang Gung Memorial HospitalIkke rekrutterer endnuAtletiske skader | Eksematiske hudsygdomme | Skin Avulsion
-
ScotiadermIkke rekrutterer endnuIntertrigo | Inkontinens-associeret dermatitis | Moisture Associated Skin Damage (MASD) (f.eks. inkontinens-associeret dermatitis [IAD], sved, dræning)
Kliniske forsøg med Iressa
-
AstraZenecaAfsluttetNeoplasmer, pladecelleForenede Stater, Tjekkiet, Polen, Tyskland, Belgien, Taiwan, Indien, Serbien
-
AstraZenecaGodkendt til markedsføringIkke-småcellet lungekræft (NSCLC)Taiwan, Thailand, Kalkun, Brasilien, Filippinerne, Den Russiske Føderation, Rumænien, Østrig, Ungarn, Bulgarien, Letland, Indien, Argentina, Australien, Estland, Malaysia, Mexico, Singapore, Sydafrika
-
Hunan Kelun Pharmaceutical Co., Ltd.AfsluttetBioækvivalensundersøgelse
-
Stanford UniversityAstraZeneca; Ligand PharmaceuticalsAfsluttet
-
Hunan Kelun Pharmaceutical Co., Ltd.Afsluttet
-
Chonnam National University HospitalAstraZenecaAfsluttetKarcinom, ikke-småcellet lungeKorea, Republikken
-
Asan Medical CenterAstraZenecaUkendt
-
ZhuGuangYingZhejiang Cancer Hospital; 307 Hospital of PLA; Fudan University; Cancer Institute... og andre samarbejdspartnereUkendt
-
University of ChicagoAfsluttet